title: A randomized crossover study of medroxyprogesterone acetate and Diane-35 in adolescent girls with polycystic ovarian syndrome.
abstract: OBJECTIVE
  To investigate the effects of 4-month treatment of medroxyprogesterone acetate (MPA) and Diane-35 on the clinical and biochemical features of hyperandrogenism and quality of life of adolescent girls with polycystic ovarian syndrome (PCOS).
  
  
  METHODS
  A prospective, randomized, cross-over study.
  
  
  METHODS
  An accredited pediatric and adolescent gynecology clinic of a university-affiliated tertiary hospital.
  
  
  METHODS
  76 adolescents girls aged 14 to 19 years old with PCOS were recruited from July 2007 to July 2010.
  
  
  METHODS
  Girls were randomized into 2 groups. Group 1 received oral MPA for 4 months, followed by a washout period of 4 months, and then Diane-35 for another 4 months. Group 2 received the same combination but in the reverse order.
  
  
  METHODS
  Clinical and biochemical features of hyperandrogenism and quality of life were assessed.
  
  
  RESULTS
  There was no significant difference between the 2 groups at baseline. No significant difference was found in the clinical and biochemical parameters of hyperandrogenism before and after treatment with MPA. Significant reduction of the acne score, LH/FSH ratio, and testosterone level was seen after taking Diane-35. Hirsutism was also improved but it did not reach statistical significant. When comparing post-MPA and post-Diane-35, the post-Diane-35 group had significantly improved acne score and LH/FSH ratio. No significant difference was found on quality of life between both groups after treatment.
  
  
  CONCLUSIONS
  Diane-35 may be a more suitable treatment option in adolescent girls diagnosed with PCOS when compared to MPA.
authors.affiliation: Department of Obstetrics and Gynaecology, The Chinese University of Hong Kong, Prince of Wales Hospital, New Territories, Hong Kong. Electronic address: jacquelinechung@cuhk.edu.hk.
authors.forename: Jacqueline P W
authors.initials: JP
authors.lastname: Chung
authors.affiliation: Department of Obstetrics and Gynaecology, The Chinese University of Hong Kong, Prince of Wales Hospital, New Territories, Hong Kong.
authors.forename: Alice K W
authors.initials: AK
authors.lastname: Yiu
authors.affiliation: Department of Obstetrics and Gynaecology, The Chinese University of Hong Kong, Prince of Wales Hospital, New Territories, Hong Kong.
authors.forename: Tony K H
authors.initials: TK
authors.lastname: Chung
authors.affiliation: Department of Obstetrics and Gynaecology, The Chinese University of Hong Kong, Prince of Wales Hospital, New Territories, Hong Kong.
authors.forename: Symphorosa S C
authors.initials: SS
authors.lastname: Chan
mesh_terms: D000152:Acne Vulgaris / Q000188:drug therapy; D000293:Adolescent; D000726:Androgen Antagonists / Q000627:therapeutic use*; D018592:Cross-Over Studies; D017373:Cyproterone Acetate / Q000627:therapeutic use*; D004338:Drug Combinations; D004997:Ethinyl Estradiol / Q000627:therapeutic use*; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood; D006628:Hirsutism / Q000188:drug therapy; D006801:Humans; D017588:Hyperandrogenism / Q000097:blood / Q000188:drug therapy* / Q000209:etiology; D007986:Luteinizing Hormone / Q000097:blood; D017258:Medroxyprogesterone Acetate / Q000627:therapeutic use*; D011085:Polycystic Ovary Syndrome / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D011446:Prospective Studies; D011788:Quality of Life; D012720:Severity of Illness Index; D013739:Testosterone / Q000097:blood; D055815:Young Adult
chemical_list: D000726:Androgen Antagonists; D004338:Drug Combinations; D013739:Testosterone; D004997:Ethinyl Estradiol; D017373:Cyproterone Acetate; C032640:Cyproterone acetate, ethinyl estradiol drug combination; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone; D017258:Medroxyprogesterone Acetate
keywords: Adolescents; Cyproterone acetate; Medroxyprogesterone acetate; Polycystic ovarian syndrome; Quality of life